Merck Millipore Announces Co-marketing Agreement with groninger
News Aug 13, 2013
Merck Millipore has announced a co-marketing agreement with groninger, a leading provider of filling and packaging equipment for the pharmaceutical industry.
Moving forward, Merck Millipore will be groninger's partner of choice for single-use technology and groninger will be Merck Millipore's partner of choice for filling equipment.
Under the non-exclusive agreement, Merck Millipore will provide single-use filling products for use in conjunction with groninger's liquid filling equipment.
Merck Millipore's Mobius® single-use final fill assemblies offer greater flexibility than traditional options, allowing biopharmaceutical manufacturers to produce a variety of drug products and fill volumes with reduced process turnaround time and higher productivity.
By combining them with groninger's world-class liquid fill equipment, the co-marketing agreement will help customers accelerate the development and time-to-market of biopharmaceutical therapeutics.
Merck Millipore offers a full range of products, including Durapore® and Millipore Express® membranes for sterile filtration, the NovaSeptum® system for sterile sampling, the Lynx family® of sterile connectors and Provantage® Services for sterility training and qualification.
Taken together, Merck Millipore's sterility assurance solutions help biopharmaceutical manufacturers deliver a safe final product.
"The biopharmaceutical industry is facing increasingly complex drug production demands, as therapeutic drugs in development have smaller lot sizes and highly potent ingredients," said Vin Donovan, Vice President of Biopharm Process Solutions.
Donovan continued, "This new partnership will allow us to help our customers address these new challenges while ensuring the safety of their filling operations. This new agreement reflects our commitment to growing our relationships with top-tier partners to better enhance our industry solutions."
Synthetic biologists look to re-engineer cells to make complex molecules for specific needs, including pharmaceuticals. But the trial-and-error process is difficult and time-consuming. Now, by combining two state-of-the-art research approaches, researchers have created a fast, efficient way to engineer and analyze metabolic pathways.READ MORE